Liese Barbier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8036281/publications.pdf

Version: 2024-02-01

		1477746	1281420	
12	269	6	11	
papers	citations	h-index	g-index	
13 all docs	13 docs citations	13 times ranked	235 citing authors	

#	Article	IF	CITATIONS
1	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clinical Pharmacology and Therapeutics, 2020, 108, 734-755.	2.3	86
2	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. British Journal of Cancer, 2019, 121, 199-210.	2.9	48
3	European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption. BioDrugs, 2020, 34, 783-796.	2.2	39
4	European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice. BioDrugs, 2020, 34, 797-808.	2.2	33
5	Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices. Pharmaceuticals, 2021, 14, 499.	1.7	18
6	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Frontiers in Medicine, 2022, 9, 820755.	1.2	16
7	Interchangeability of Biosimilars: Overcoming the Final Hurdles. Drugs, 2021, 81, 1897-1903.	4.9	11
8	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. Journal of Pharmaceutical Policy and Practice, 2021, 14, 53.	1.1	7
9	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology, 2021, 12, 789640.	1.6	6
10	Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. Exploratory Research in Clinical and Social Pharmacy, 2021, 4, 100084.	0.6	2
11	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. Frontiers in Pharmacology, $0,13,.$	1.6	2
12	When Will American Patients Start Benefitting From Biosimilars?. Mayo Clinic Proceedings, 2022, 97, 1044-1047.	1.4	1